582
H. Takeda et al.
LETTER
(6) (a) For the attempted catalytic asymmetric IMCP of 2-diazo-
3-oxo-6-heptenoic acid esters, see ref. 5a. (b) He, M.;
Tanimori, S.; Ohira, S.; Nakayama, M. Tetrahedron 1997,
53, 13307. (c) Mühler, P.; Boléa, C. Helv. Chim. Acta 2001,
84, 1093.
Acknowledgment
This work was financially supported in part by a Waseda University
Grant for Special Research Projects and a Grant-in-Aid for Scienti-
fic Research on Priority Areas (Creation of Biologically Functional
Molecules; No. 17035082) from the Ministry of Education, Culture,
Sports, Science, and Technology (MEXT), Japan. We are also
indebted to 21COE ‘Practical Nano-Chemistry.’ The fellowship
for young scientists to M.H. from JSPS is also gratefully acknow-
ledged.
(7) (a) Honma, M.; Sawada, T.; Fujisawa, Y.; Utsugi, M.;
Watanabe, H.; Umino, A.; Matsumura, T.; Hagihara, T.;
Takano, M.; Nakada, M. J. Am. Chem. Soc. 2003, 125,
2860. (b) Honma, M.; Nakada, M. Tetrahedron Lett. 2003,
44, 9007. (c) Sawada, T.; Nakada, M. Adv. Synth. Catal.
2005, 347, 1527. (d) Takeda, H.; Nakada, M. Tetrahedron:
Asymmetry 2006, 17, 2896. Total synthesis of natural
products utilizing the catalytic asymmetric IMCP of a-
diazo-b-keto sulfones: (e) (–)-Allocyathin B2: Takano, M.;
Umino, A.; Nakada, M. Org. Lett. 2004, 6. (f) (–)-
Malyngolide: Miyamoto, H.; Iwamoto, M.; Nakada, M.
Heterocycles 2005, 66, 61. (g) (–)-Methyl jasmonate:
Takeda, H.; Watanabe, H.; Nakada, M. Tetrahedron 2006,
62, 8054.
References and Notes
(1) Reviews for the preparation and use of cyclopropanes:
(a) Wong, H. N. C.; Hon, M.-Y.; Tse, C.-W.; Yip, Y.-C.;
Tanko, J.; Hudlicky, T. Chem. Rev. 1989, 89, 165.
(b) Davies, H. M. L. Comprehensive Organic Synthesis, Vol.
4; Trost, B. M.; Fleming, I., Eds.; Pergamon: Oxford, 1991,
Chap. 4.8, 1031–1067. (c) Ye, T.; McKervey, M. A. Chem.
Rev. 1994, 94, 1091. (d) Doyle, M. P.; Protopopova, M. N.
Tetrahedron 1998, 54, 7919. (e) Doyle, M. P. Catalytic
Asymmetric Synthesis, 2nd ed.; Ojima, I., Ed.; YHC
Publishers: New York, 2000, Chap. 5, 191–228; and
references cited therein.
(2) (a) Kondo, K.; Takahatake, Y.; Sugimoto, K.; Tunemoto, D.
Tetrahedron Lett. 1978, 907. (b) Tanimori, S.; Kainuki, T.;
Nakayama, M. Biosci., Biotechnol., Biochem. 1992, 56,
1807.
(3) (a) Nemoto, H.; Wu, X. M.; Kurobe, H.; Ihara, M.;
Fukumoto, K.; Kametani, T. Tetrahedron Lett. 1983, 24,
4257. (b) Wilson, S. R.; Haque, M. S.; Venkatesan, A. M.;
Zucker, P. A. Tetrahedron Lett. 1984, 25, 3151.
(8) General Procedure.
A toluene azeotroped [CuOTf]2·toluene (7.7 mg, 0.0148
mmol, 10 mol% as CuOTf) was placed in a dried flask under
Ar atmosphere. To this flask was added toluene (4 mL) and
then a solution of toluene azeotroped ligand 3c (13.1 mg,
0.0445 mmol, 15 mol%) in toluene (2 × 0.5 mL) via a
cannula. The mixture was stirred at r.t. for 0.5 h and then a
solution of toluene azeotroped 2,6-di-tert-butyl-4-methyl-
phenyl 2-diazo-3-oxo-6-heptenoate (10, 110.0 mg, 0.297
mmol) in toluene (2 × 0.5 mL) was added to the light blue
solution via a cannula. The reaction mixture was stirred at 50
°C for 45.5 h, quenched with a mixture of sat. aq NH4Cl
solution (1 mL) and NH4OH aq solution (3 mL), and
extracted with Et2O (2 × 2 mL). The combined organic layer
was washed with brine (2 mL), dried over Na2SO4, and eva-
porated. The residue was purified by flash chromatography
(hexane–EtOAc, 10:1) to afford 2-oxobicyclo[3.1.0]hexane-
1-carboxylic acid 2,6-di-tert-butyl-4-methylphenyl ester
(14, 57.0 mg, 56%, 78% ee) as a white solid. The absolute
configuration was determined as described in the text. The
ee was determined as described in ref. 9: [a]D28 –23.0 (c 0.45,
CHCl3, 78% ee). IR (KBr): nmax = 2984, 1761, 1727, 1324,
1264, 1189, 1139, 1076, 1033, 781, 714 cm–1. 1H NMR (400
MHz, CDCl3): d = 7.09 (s, 1 H), 7.08 (8) (s, 1 H), 2.76 (ddd,
J = 8.1, 5.4, 5.4 Hz, 1 H), 2.38–2.06 (m, 9 H including d =
2.31, s, 3 H), 1.37 (s, 9 H), 1.30 (s, 9 H). 13C NMR (100
MHz, CDCl3): d = 205.3, 169.2, 145.7, 142.1, 141.7, 134.5,
126.9, 38.2, 35.3, 35.1, 34.2, 34.0, 31.4 (4), 31.4, 23.3, 21.5,
20.8. HRMS–FAB: m/z calcd for C22H30O3 + H: 343.2273;
found: 343.2285.
(c) Nemoto, H.; Wu, X. M.; Kurobei, H.; Minemura, K.;
Ihara, M.; Fukumoto, K.; Kametani, T. J. Chem. Soc., Perkin
Trans. 1 1985, 1185. (d) Nemoto, H.; Kimura, T.; Kurobe,
H.; Fukumoto, K.; Kametani, T. J. Chem. Soc., Perkin
Trans. 1 1986, 1777. (e) Taber, D. F.; Amedio, J. C. Jr.;
Raman, K. J. Org. Chem. 1988, 53, 2984. (f) Wilson, S. R.;
Venkatesan, A. M.; Augelli-Szafran, C. E.; Yasmin, A.
Tetrahedron Lett. 1991, 32, 2339. (g) Moriarty, R. M.; Kim,
J.; Guo, L. Tetrahedron Lett. 1993, 34, 4129. (h) Tanimori,
S.; Tsubota, M.; He, M.; Nakayama, M. Synth. Commun.
1997, 27, 2371.
(4) Taber, D. F.; Saleh, S. A.; Korsmeyer, R. W. J. Org. Chem.
1980, 45, 4699.
(5) (a) Dauben, W. G.; Hendricks, R. T.; Luzzio, M. J.; Ng, H.
P. Tetrahedron Lett. 1990, 31, 6969. (b) Pique, C.;
Fahndrich, B.; Pfaltz, A. Synlett 1995, 491; Special Issue.
(c) Park, S.-W.; Son, J.-H.; Kim, S.-G.; Ahn, K. H.
Tetrahedron: Asymmetry 1999, 10, 1903. (d) Kim, S. G.;
Cho, C. W.; Ahn, K. H. Tetrahedron 1999, 55, 10079.
(e) Barberis, M.; Estevan, F.; Lahuerta, P.; Perez-Prieto, J.;
Sanau, M. Inorg. Chem. 2001, 40, 4226. (f) Barberis, M.;
Perez-Prieto, J.; Stiriba, S.-E.; Lahuerta, P. Org. Lett. 2001,
3, 3317. (g) Saha, B.; Uchida, T.; Katsuki, T. Chem. Lett.
2002, 8, 846. (h) Barberis, M.; Perez-Prieto, J.; Herbst, K.;
Lahuerta, P. Organometallics 2002, 21, 1667. (i) Saha, B.;
Uchida, T.; Katsuki, T. Tetrahedron: Asymmetry 2003, 14,
823. (j) Wong, A.; Welch, C. J.; Kuethe, J. T.; Vazquez, E.;
Shaimi, M.; Henderson, D.; Davies, I. W.; Hughes, D. L.
Org. Biomol. Chem. 2004, 2, 168. (k) Estevan, F.; Lahuerta,
P.; Lloret, J.; Perez-Prieto, J.; Werner, H. Organometallics
2004, 23, 1369. (l) Estevan, F.; Lahuerta, P.; Lloret, J.;
Penno, D.; Sanau, M.; Ubeda, M. A. J. Organomet. Chem.
2005, 690, 4424. (m) Uchida, T.; Katsuki, T. Synthesis
2006, 1715.
(9) Compound 12: DAICEL CHIRALCEL OD-H ∅ 0.46 cm ×
25 cm; hexane–2-PrOH = 9:1; flow rate = 0.5 mL/min); tR =
15.0 min for ent-12, 18.2 min for 12.
Compound 13: DAICEL CHIRALPAK AS-H ∅ 0.46 cm ×
25 cm; hexane–2-PrOH = 4:1; flow rate = 0.5 mL/min); tR =
25.8 min for ent-13, 28.8 min for 13.
Compound 14 was converted into its oxime, which was
benzoylated and subjected to HPLC analysis: DAICEL
CHIRALCEL OD-H ∅ 0.46 cm × 25 cm; hexane–2-PrOH =
14:1; flow rate = 0.2 mL/min); tR: 25.8 min for ent-14, 28.8
min for 14.
Synlett 2007, No. 4, 579–582 © Thieme Stuttgart · New York